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tions.12 TCM cells express molecules such as CD62L and CCR7, 
which allow efficient homing to lymph nodes, whereas TEM 
cells lack expression of these lymph node homing receptors 
and are located in nonlymphoid tissues. However, both T 
cell subsets are present in the blood and spleen. Some stud-
ies have also shown that TEM cells acquire effector functions, 
such as cytokine production and killing, more rapidly than 
do TCM.13-15
The induction of immunological tolerance is an important 
clinical goal in autoimmunity. Strategies designed specifi-
cally to suppress the function of chronically activated mem-
ory T cells without impairing the function of naïve T cells 
therefore have value in the treatment of autoimmune dis-
eases. Two signals are required for T cell activation: antigen 
recognition and costimulatory signals. Several costimulatory 
pathways important in the activation of T cells have been 
identified.16,17 Costimulatory molecules may deliver either a 
stimulatory (positive) or inhibitory (negative) signal for T cell 
activation.18 The delicate balance between positive and nega-
tive regulatory signals can determine the outcome of a spe-
cific immune response. It has been suggested that memory 
T cells are less dependent on positive costimulatory signals 
than naïve cells for activation on antigen encounter11,19,20 or 
may require different costimulatory signals. In humans, ex 
vivo activated myelin-reactive T cells from multiple sclerosis 
patients are independent of CD28-B7 costimulation.7,9 How-
ever, in vivo murine studies showed that activation of effec-
tor-memory CD4+ T cells may be abrogated by blocking the 
CD28-B7 pathway.21 Furthermore, it was recently shown that 
memory CD8+ T cells require CD28 costimulation to generate 
maximal secondary responses against pathogens.22
Experimental autoimmune encephalomyelitis (EAE) is an 
inflammatory disease of the central nervous system that 
mimics certain aspects of MS. Although no animal model can 
Multiple sclerosis (MS) is a chronic inflammatory demy-
elinating disease of the central nervous system (CNS) white 
matter in which T cells and their mediators trigger injury of 
axons and their myelin sheaths through a complex sequence 
of events.1-5 T cell-mediated inflammation is driven by an au-
toimmune process, which in turn can trigger a degenerative 
phase that is independent of immune responses.2 Although 
the nature of the autoreactive T cells in MS patients is not yet 
fully understood, there is evidence that these T cells belong 
to the long-lived memory T cell pool.6-9
Memory CD4+ T cells express a pattern of surface markers 
different from that of naïve or effector cells, and their re-
sponses to immune stimuli are functionally different.10 Mu-
rine memory cells are high in CD44 and low in the expression 
of activation markers such as CD25. Memory cells can persist 
in the absence of antigenic stimulation as nondividing cells.10 
Re-encounter with the same antigen can expand the popula-
tion to a stable, higher level and generate a separate popula-
tion of CD44 high effector T cells.11 Two subsets of memory 
T cells, called central-memory (TCM) and effector-memory 
(TEM) T cells, are described based on their anatomical loca-
tion, expression of cell surface markers, and effector func-
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Distinct Functions of Autoreactive Memory and Effector CD4+ T Cells in Experimental Autoimmune 
Encephalomyelitis
Wassim Elyaman,* Pia Kivisäkk,* Jay Reddy,* Tanuja Chitnis,* Khadir Raddassi,* Jaime Imitola,* Elizabeth Brad-
shaw,* Vijay K. Kuchroo,* Hideo Yagita,‡ Mohamed H. Sayegh,† and Samia J. Khoury*
From the Center for Neurologic Diseases,* Brigham and Women’s Hospital, and Transplantation Center,† Brigham and Women’s Hospital and 
Children’s Hospital, Harvard Medical School, Boston, Massachusetts; and Department of Immunology,‡ Juntendo University School of Medi-
cine, Tokyo, Japan
The persistence of human autoimmune diseases is thought to be mediated predominantly by memory T cells. We investigat-
ed the phenotype and migration of memory versus effector T cells in vivo in experimental autoimmune encephalomyelitis 
(EAE). We found that memory CD4+ T cells up-regulated the activation marker CD44 as well as CXCR3 and ICOS, prolifer-
ated more and produced more interferon-γ and less interleukin-17 compared to effector T cells. Moreover, adoptive transfer 
of memory T cells into T cell receptor (TCR)αβ-/- recipients induced more severe disease than did effector CD4+ T cells with 
marked central nervous system inflammation and axonal damage. The uniqueness of disease mediated by memory T cells 
was confirmed by the differential susceptibility to immunomodulatory therapies in vivo. CD28-B7 T cell costimulatory signal 
blockade by CTLA4Ig suppressed effector cell-mediated EAE but had minimal effects on disease induced by memory cells. 
In contrast, ICOS-B7h blockade exacerbated effector T cell-induced EAE but protected from disease induced by memory T 
cells. However, blockade of the OX40 (CD134) costimulatory pathway ameliorated disease mediated by both memory and 
effector T cells. Our data extend the understanding of the pathogenicity of autoreactive memory T cells and have important 
implications for the development of novel therapies for human autoimmune diseases.
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(clone HK5.3)24 and anti-OX40L (clone RM 134L)25 were pro-
duced by Bioexpress Cell Culture Inc. (Kaysville, Utah) and 
administered to mice intraperitoneally at 200 μg starting from 
the day of the immunization and every other day until day 
10 postimmunization. Control IgG antibodies were given ac-
cording to the same protocol. For ELISPOT assay, 96-well ni-
trocellulose plates (Millipore, Bedford, Massachusetts) were 
coated with 4 μg/ml purified mouse anti-interferon (IFN)-γ, 
anti-interleukin (IL)-10 (all from BD Biosciences, San Diego, 
California), and anti-IL-17 (ELISPOT kit; eBioscience, San 
Diego, California) overnight at 4°C. After blocking with 1% 
BSA, 2 to 5 × 105 cells were loaded in each well and incubated 
with 0 to 100 μg/ml antigen peptide for 36 hours at 37°C. 
After washing, corresponding plates were incubated with 2 
μg/ml biotinylated anti-IFN-γ, anti-IL-10, or anti-IL-17 over-
night at 4°C. The plates were washed, then incubated with 
alkaline phosphatase (Sigma, St. Louis, Missouri) at 1:10,000 
for 2 hours at room temperature, and developed in BCIP/
NBT (Sigma) solution. Spots were counted using a comput-
er-assisted ELISPOT Image Analyzer (Cellular Technology 
Limited, Cleveland, Ohio). IFN-γ (ELISA kit; R&D Systems, 
Minneapolis, Minnesota) production was assessed in the cul-
ture supernatants by ELISA 2 days after ex vivo stimulation 
according to the manufacturer’s protocol.
Intracellular Cytokine Staining
Cells were isolated from peripheral tissues or from the CNS 
and were restimulated with phorbol 12-myristate 13-acetate 
(20 ng/ml), ionomycin (300 ng/ml), and 2 mmol/L mon-
ensin (GolgiStop; BD PharMingen, San Diego, California) for 
4 hours at 37°C. Cells were washed and stained for surface 
markers by incubating at room temperature for 20 minutes. 
After two washes in PBS containing 2% FCS and 0.1% sodi-
um azide, the cells were treated with 1% paraformaldehyde 
and fixed with buffer containing saponin according to the 
manufacturer’s recommendations (BD PharMingen). Fol-
lowing permeabilization, the phycoerythrin (PE)-conjugated 
anti-cytokine antibodies were added for 20 minutes at room 
temperature, and the cells were washed and analyzed by 
using a FACSCalibur Flow Cytometer (BD Biosciences, San 
Jose, California). Cytokine Abs and their corresponding iso-
type controls from BD PharMingen, IL-4, IL-17, and IFN-γ, 
were used.
Confocal Microscopy
For immunohistochemistry, animals were sacrificed and 
perfused with 4% paraformaldehyde in PBS; then, brain and 
spinal cord tissues were harvested and postfixed, dehydrat-
ed with 30% sucrose, placed in optimal cutting temperature, 
and stored at −80°C until use. The following antibodies were 
purchased from BD PharMingen: rat anti-CD4 (1:100), rabbit 
anti-glial fibrillary acidic protein (GFAP) (1:100), rabbit anti-
lectin B4 (1:100), mouse anti-SMI32 (1:100), rhodamine goat 
anti-rat (1:250), fluorescein isothiocyanate (FITC) goat anti-
rabbit (1:500), and FITC goat anti-mouse (1:500). Thirty-μm-
thick longitudinal sections of spinal cord tissues from mice 
exhibiting EAE, and control mice were washed with PBS, 
then blocked in PBS containing 8% horse serum, 3% BSA, and 
0.3% Triton X-100. The sections were incubated with prima-
replicate MS completely, this model is valuable in addressing 
specific questions of pathogenesis and potential therapies. 
However, most studies have focused on targeting prevention 
of disease or therapy of early disease that may not be fully 
applicable to human disease, which is probably perpetuated 
by memory T cells. The understanding of CD4+ memory T 
cell function and regulation comes mostly from in vitro stud-
ies or limited in vivo studies, but there is no disease model 
mediated purely by memory T cells. Here we establish a new 
EAE disease model mediated by antigen-specific memory 
CD4+ T cells generated in vivo. Our data show that memory 
CD4+ T cells induce more severe disease than effector CD4+ 
T cells caused by a preferential differentiation of memory T 
cells into the Th1 phenotype and a differential expression of 
chemokine receptors and costimulatory molecules leading 
to severe CNS inflammation. Furthermore, our data using 
costimulatory blocking agents show the requirement of the 
Inducible costimulator-B7h and OX40 pathways in disease 
mediated by memory CD4+ T cells. Our findings have im-
plications for the treatment of human autoimmune diseases 
and translating novel tolerance strategies to the clinic.
Materials and Methods
Mice and EAE Induction with Myelin Oligodendrocytes Gly-
coprotein (MOG)
Female wild-type (WT) and T cell receptor (TCR)αβ-/- 
C57BL/6 mice were purchased from The Jackson Laboratory 
(Bar Harbor, Maine). MOG-TCR mice (2D2) were provided by 
V. Kuchroo (Brigham and Women’s Hospital, Boston, Mas-
sachusetts). All animal experiments were performed with the 
approval of the Harvard Medical Area Standing Committee 
on Animals. EAE was induced in C57BL/6 WT and TCRαβ-/- 
mice as described previously.23 MOG peptide 35-55 (M-E-V-
G-W-Y-R-S-P-F-S-R-O-V-H-L-Y-R-N-G-K), corresponding to 
the mouse sequence, was synthesized by Quality Controlled 
Biochemicals Inc., a division of Biosource International (Hop-
kinton, Massachusetts) and purified to greater than 99% by 
high-performance liquid chromatography. C57BL/6 WT and 
TCRαβ-/- mice were immunized subcutaneously in the flank 
with 100 μg of myelin oligodendrocyte glycoprotein peptide 
of amino acids 35-55 (MOG35-55) peptide in 0.1 ml of PBS 
and 0.1 ml of complete Freund’s adjuvant (CFA) containing 
0.4 mg of Mycobacterium tuberculosis (H37Ra; Difco Laborato-
ries, Detroit, Michigan) and injected intraperitoneally with 
200 ng of pertussis toxin (PT) (List Biological Laboratories 
Inc., Campbell, California) on the day of immunization and 2 
days later. For clinical scoring, animals were kept for at least 
1 month and EAE was scored as follows: grade 1, limp tail or 
isolated weakness of gait without limp tail; grade 2, partial 
hind and front leg paralysis; grade 3, total hind leg paralysis; 
grade 4, total hind leg and partial front leg paralysis; grade 5, 
moribund or dead animal.
Antibodies, Reagents, Enzyme-Linked Immunosorbent Spot 
(ELISPOT) Assay, and Enzyme-Linked Immunosorbent As-
say (ELISA)
Murine CTLA4Ig was obtained from Bristol-Myers Squibb 
(Seattle, Washington). Anti-ICOS-L monoclonal antibody 
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MHC II IAb Tetramer Staining Based on Flow-Cytometric 
Analysis
The MHC II IAb tetramer was provided by V. Kuchroo. Four 
days after the activation of lymphoid cells, cell suspensions 
were enriched for T cells by Ficoll-Hypaque density gradient 
centrifugation. As a control for the tetramer, another group 
of C57BL/6 mice was immunized for 14 or 100 days with 
ovalbumin (100 μg) in CFA + PT, and splenocytes were used 
for the tetramer staining. The cells from all groups were incu-
bated with IAb multimers (30 μg/ml) in Dulbecco’s modified 
Eagle’s medium supplemented with IL-2 (5 μmol/L) at 37°C 
for 3 hours. The cells were then washed and stained with 
anti-CD4 (CD4-Allophycocyanin) and 7-AAD (BD PharMin-
gen). After incubating at room temperature for 20 minutes, 
the cells were washed and analyzed using a FACSort (BD 
Biosciences). The number of cells positive for tetramer-PE 
(MOG35-55) was then determined in live (7-AAD-negative), 
CD4-positive populations.
Statistical Analysis
The two-tailed Mann-Whitney and unpaired t-tests were 
used to compare disease, cell proliferation, and cytokine 
production. Fisher’s exact test was used to compare disease 
incidence.
Results
Characterization of Autoreactive Memory CD4+ T Cells
We isolated CD4+CD44hi T cells from C57BL/6 mice after re-
covery from acute disease, greater than 100 days after immu-
nization with MOG35-55 in CFA and intraperitoneal injec-
tions of PT. Effector CD4+ T cells (CD4+CD44hi) were isolated 
directly from short-term MOG-immunized mice around the 
peak of the clinical disease (12 days). Both memory and ef-
fector CD4+ T cells express the activation molecule CD44, but 
memory T cells express significantly higher levels of CD44 
compared to effector CD4+ T cells (P = 0.002 by paired t-test) 
and slight down-regulation of CD62L expression (see Sup-
plementary Figure S1A, at http://ajp.amjpathol.org). One of 
the defining features of memory CD4+ T cells is their sur-
vival advantage mediated by up-regulation of anti-apoptotic 
molecules.26-28 We compared the survival of memory CD4+ 
T cells to that of effector CD4+ T cells isolated as described 
above and stimulated in vitro with MOG35-55 peptide (0, 1, 
and 10 μg/ml) at equal numbers (0.5 × 106/well) for 4 days 
in a 96-well plate. We found higher percentages of Annexin 
V binding cells in 7-AADneg/CD4+CD44hi in effector T cells 
compared to memory T cells. However, there was no dif-
ference in the 7-AADpos/CD4+CD44hi gate between the two 
populations (see Supplementary Figure S1B, at http://ajp.
amjpathol.org). The ability of memory cells to resist activa-
tion-induced cell death is due, at least partially, to higher 
expression of the anti-apoptotic protein Bcl-2, as shown by 
Western blot, of freshly isolated memory CD4+ T cells from 
long-term MOG35-55-immunized mice compared to effector 
cells isolated from short-term immunized mice (see Supple-
mentary Figure S1C, at http://ajp.amjpathol.org). More-
over, carboxyfluorescein succinimidyl ester (CFSE) label-
ry antibodies overnight at 4°C, washed, and incubated with 
the appropriate combination of secondary antibodies for 1 
hour in blocking buffer. The sections were stained with the 
nuclear stain, TOTO-3 (Molecular Probes, Carlsbad, Califor-
nia), and mounted, and images were captured using confocal 
imaging and LSM510 software (Zeiss, Jena, Germany). Av-
eraged numbers of CD4 and lectin B4-positive cells from at 
least three different levels of sectioning per spinal cord (two 
samples per group) were counted under X63 magnification.
T Cell Preparation, Phenotyping, and Adoptive Transfer
The memory CD4+ cell populations were characterized by 
flow-cytometric analysis using rat anti-CD44-FITC, CD62L-
Allophycocyanin, ICOS-PE, CD28-PE, CTLA4-FITC, OX40-
PE, (CXC chemokine receptor 3)-PE, and appropriate isotype 
antibody controls (all purchased from BD Biosciences). PE 
anti-mouse CCR7 and T-bet were from eBioscience (San Di-
ego, California). For adoptive transfer studies, splenocytes 
from naïve, primed (immunized with MOG35-55 for 12 days), 
and long-term immunized mice (immunized with MOG for 
100 days) were pooled separately and enriched for CD4+ T 
cells (negative selection) by magnetic cell separation (MACS) 
(Miltenyi Biotech, Auburn, California). The CD4+ cells were 
quantified, stained with rat anti-mouse CD44-FITC, and sort-
ed using a BD FACSAria cell sorter (BD Biosciences). Finally, 
1 to 1.5 × 106 sorted naïve, effector, or memory CD4+ T cells 
were adoptively transferred by i.v. injection into TCRαβ-/- re-
cipients. Mice were immunized in the flank with MOG/CFA 
and injected intraperitoneally with 200 ng of pertussis toxin 
on the day of immunization and 2 days later.
Activation-Induced Cell Death
Splenocytes were isolated from B6 mice immunized with 
MOG35-55/CFA for 10 days (effector cells) or for more than 
120 days (memory cells). After activation with MOG peptide 
(0 to 25 μg/ml) in vitro for 4 days, cells were stained with 
7-amino-actinomycin D (7-AAD) (BD Biosciences) and An-
nexin V (BD Biosciences), followed by fluorescence-activated 
cell sorting (FACS) analysis, and the percentage of apoptotic 
cells was quantitated.
Western Blot
The anti-Bcl-2 antibody was purchased from Santa Cruz 
Biotechnology (Santa Cruz, California), and the immunoblot 
technique was performed according to standard protocols.
Expression Analysis by Real-Time PCR
Total RNA was extracted from specific cell populations us-
ing the Stratagene (La Jolla, California) RNA kit and trans-
ferred directly into the RT-PCR using the Applied Biosys-
tems Taqman kit (Applied Biosystems, Foster City, Califor-
nia). Samples were subjected to real-time PCR analysis on 
an Applied Biosystems PRISM 7000 Sequencer Detection 
System under standard conditions. Genes analyzed were de-
tected using commercially available assays (Applied Biosys-
tems). Relative mRNA abundance was normalized against 
glyceraldehyde-3-phosphate dehydrogenase.
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ory T cell population (∼15-fold increase) (see Supplementary 
Figure S2D, at http://ajp.amjpathol.org). We also measured 
the frequency of T-bet-positive cells by intracellular staining. 
The number of T-bet-positive cells was higher in the memory 
cell population compared to the effector T cells (22.3 ± 5.1 
versus 12.6 ± 3.9, P <0.01), although their mean fluorescence 
intensity levels were identical (data not shown).
Memory CD4+ T Cells Induce More SevereDisease Than Ef-
fector Cells
CD4+CD44hi memory T cells from long-term (100 days) 
immunized WT mice were sorted and transferred into lym-
phopenic TCRαβ-/- mice by i.v. injection. Effector CD4+CD44hi 
and naïve CD4+CD62L+ cells isolated fromimmunized (12 
days) and non-immunized WT mice, respectively, were used 
as controls. Following cell transfer, recipients were immu-
nized with MOG35-55/CFA + PTand observed for EAE de-
velopment. Although EAE onset was similar between recipi-
ents of memory and effector cells, disease was significantly 
more severe in memoryCD4+ cell-induced disease compared 
to that induced by effector T cells (mean maximal score 3.0 ± 
0.2 versus 2.2 ± 0.2, P = 0.006 by Mann-Whitney test). As ex-
pected, adoptive transfer of naïve T cells caused a mild and 
delayed EAE compared to disease induced by memory cells 
(mean maximal score 3.0 ± 0.2 versus 0.8 ± 0.4, P < 0.0001 
by Mann-Whitney test) (Figure 1A; Table 1). The enhanced 
disease severity was not due to unequal frequency of MOG-
specific cells at the time of transfer, since the precursor fre-
quency of IAb-MOG35-55tetramer. cells was actually in favor 
of the effector cell population (Figure 1B).
To analyze the peripheral immune responses of the trans-
ferred cells, we isolated draining lymph nodes and spleno-
cytes from TCRαβ-/- mice recipients of memory or effector 
CD4+ T cells 12 days after immunization. Cells from the 
memory T cell recipient group exhibited more proliferation 
than those from the effector T cell recipients after culture 
with 10 and 100 μg of MOG peptide in vitro (P < 0.001 and 
P < 0.01, respectively) (Figure 1C). The cytokine production 
of freshly isolated memory or effector cells showed that the 
frequency of IFN-γ-producing cells by intracellular staining 
was significantly higher in the memory cell population (15.6 
± 2.9 versus 7.6 ± 4.6, P < 0.05). We also observed that mem-
ory T cells produced slightly more IL-17 than effector cells 
(2.6 ± 0.9 compared to 1.1 ± 0.6) (Figure 1D). There was no 
difference in the frequency of cells producing IL-4 between 
the two groups (Figure 1D).
The heightened response in the memory recipients was 
not due to unequal homeostatic proliferation of the memory 
and effector T cells. We adoptively transferred CFSE-labeled 
MOG-specific effector or memory CD4+ T lymphocytes into 
naïve TCRαβ-/- mice. Three, 6 and 10 days after adoptive 
transfer, spleen cells were isolated and the percentage of cells 
that underwent proliferation was calculated based on the 
CFSE dilutions as percentage of CFSEdim cells of alive CD4. 
cells (7-AADneg/Annexin-Vneg). We found that effector T cells 
expanded more than memory T cells at 3 and 6 days after 
transfer, but by day 10 the expansion was similar (see Supple-
mentary Figure S3, at http://ajp.amjpathol.org). These data 
exclude a possible role of homeostatic mechanisms increas-
ing the pool of memory T cells in the lymphopenic hosts.
ing shows that memory CD4+ T cells proliferate more than 
effector CD4+ T cells in response to MOG35-55 (10 μg/ml) 
stimulation as shown by quantification of CFSE dilution in 
the Annexin-Vneg/7-AADneg/CD4+CD44hi gate (P < 0.05) (see 
Supplementary Figure S1D, at http://ajp.amjpathol.org). In-
terestingly, although memory CD4+ T cells proliferated more 
than effector T cells only when exposed to the higher dose 
of MOG35-55 (10 μg/ml), they produced higher amounts 
of IFN-γ compared to effector T cells in response to 1 and 
10 μg/ml of MOG35-55 peptide (see Supplementary Figure 
S1E, at http://ajp.amjpathol.org).
Memory and Effector Cells Display Differential Expression 
of Survival and Costimulatory Genes
To eliminate the possibility of contamination of the mem-
ory cell pool by effector cells from the antigen depot site, 
we “parked” the cells in naïve syngeneic animals. CD4+ T 
cells were isolated from spleens of MOG-TCR transgenic 
mice (2D2) immunized with MOG35-55/CFA 14 days ear-
lier and parked in naïve B6 recipients for 100 days to gener-
ate memory T cells. CD4+ Vβ11+ Vα3.2+ T cells were sorted 
from the spleens of recipient mice with a recovery rate of 8 
to 12 × 103 cells per recipient. Using quantitative RT-PCR, 
we found a higher level of the antiapoptotic molecule Bcl-2 
(2.3-fold higher) and a lower level of the pro-apoptotic tumor 
necrosis factor receptor p55 (3.6-fold) and caspase-8 (2.4-fold) in 
the memory T cell population compared to effector CD4+ T 
cells. There was no difference in the mRNA expression of 
Bcl-xL (see Supplementary Figure S2A, at http://ajp.amj-
pathol.org). We then compared the mRNA expression of 
the costimulatory molecules CD28, ICOS, and OX40 in ad-
dition to CTLA4. In comparison to memory T cells, effector 
T cells expressed 2.5-and 2.8-fold higher levels of CD28 and 
CTLA4 mRNA, respectively. In contrast, ICOS expression 
was higher in the memory T cell population (3.3-fold), sug-
gesting different requirements for costimulation between 
the two populations. There was no significant difference in 
OX40 expression (see Supplementary Figure S2B, at http://
ajp.amjpathol.org). Finally, we quantified the transcripts of 
chemokine receptors on MOG-specific effector and memory 
CD4+ T cells. We found that CXCR3 transcripts were at their 
highest level only in memory T cells (12.4-fold) compared to 
effector T cells. Similarly, higher levels of CCR5 were also 
detected on the memory T cell population (2.3-fold) com-
pared to effector T cells. No significant differences in the lev-
els of CXCR4 and CCR7 between the two populations were 
detected (see Supplementary Figure S2C, at http://ajp.amj-
pathol.org). Since CCR7 is an important receptor for central 
memory cell homing, we compared the protein levels of this 
chemokine receptor between memory subpopulations (TCM 
and TEM) and effector cells. FACS analysis showed that al-
though TCM (CD4
+CD44hiCD62Lhi) cells express higher levels 
of CCR7 as compared to short-term activated T cells (MFI: 
785 ± 89.2 versus 456.5 ± 18.7; P < 0.05), there was no sig-
nificant difference in CCR7 protein expression between TEM 
(CD4+CD44hiCD62Llo) and activated effector T cells (MFI: 
479.3 ± 25.3 versus 456.5 ± 18.7).
Next, we measured the relative mRNA expression of the 
transcription factors T-box 21, RORγt, and GATA3. Interest-
ingly, the T-box 21 message was very prominent in the mem-
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antigen-specific memory CD4+ T cells, we generated two 
lines of 2D2 mice (MOG-TCR transgenic) that express Thy1.2 
or the Thy1.1 congenic markers. First, we showed that the 
transfer of memory T cells from 2D2 mice into TCRαβ-/- mice 
induced more severe disease than did their effector coun-
terparts (mean maximal score 3.8 ± 0.4 versus 2.8 ± 0.1, P = 
0.004 by Mann-Whitney test) (Figure 2A). Second, we stud-
ied the expansion, phenotype, and trafficking of autoreac-
tive memory and effector CD4+ T cells by transferring both 
cell types into one WT hybrid recipient. Using MOG TCR-
transgenic mice that express Thy1.2 or the Thy1.1 congenic 
markers, we tracked the Thy1.1 (memory) and Thy1.2 (effec-
tor) CD4+ T cells in the periphery before and during disease 
onset, and in the CNS compartment during the peak of the 
disease. To do this, equal numbers of MOG TCR transgenic 
Thy1.1 memory and Thy1.2 effector CD4+CD44hi T cells were 
transferred i.v. into Thy1.1/Thy1.2 hybrid hosts and chal-
lenged with MOG35-55 peptide. At the time of transfer, there 
were phenotypic differences between memory and effector 
cell populations: as measured by flow cytometry, ICOS and 
Another possible confounding factor could be unequal 
expansion of CD4+CD25+ regulatory T cells after in vivo 
transfer of the effector versus memory T cells. At the time 
of transfer, the percentage of CD4+CD25+Foxp3+ cells was 
comparable between the memory and the effector popula-
tions (8.3 ± 0.7 versus 7.5 ± 0.6, P = 0.5) (data not shown). To 
explore the possibility of unequal expansion of regulatory T 
cell populations in vivo after immunization, splenocytes iso-
lated from recipients of either effector or memory CD4+ cells 
were isolated 10 days after immunization, and the percent-
age of CD4+CD25+Foxp3 was measured. We found that the 
percentage of regulatory T cells was similar in TCRαβ-/- mice 
that received memory or effector CD4+ cells (9.7 ± 1.4 from 
the effector T cell recipients compared to 11.2 ± 0.1 in the 
memory T cell recipients, P = 0.4) (data not shown).
In Vivo Dynamics of MOG-Specific Memory and Effector 
CD4+ T Cells
To study the disease dynamics induced by the transfer of 
Figure 1. Adoptive transfer studies into TCRαβ-/- mice. A: A representative experiment showing transfer of disease in TCRαβ-/- mice. Spleens and lymph nodes from 
wild-type mice were harvested at 12 days (Effector‚ Δ) or more than 100 days (Memory, ■) postimmunization; CD4+ MACS were negative-selected and cell-sorted 
for expression of CD44. Naïve CD4+ T cells were isolated from nonimmunized mice and used as control. The cells were resuspended in PBS at a concentration of 1 × 
106/100 μl and injected i.v. into TCRαβ-/- mice. Recipients were immunized with MOG35-55 peptide on the day of transfer and graded for disease daily. The mean 
daily disease grade ± SEM for each group (n = 8 to 16 mice per group) is shown. B: Frequency of MOG-specific CD4+ T cells. Splenocytes isolated from short- or 
long-term MOG-immunized WT mice (n = 3 to 5) were activated in vitro, and the cell suspensions were enriched for T cells by Ficoll-Hypaque density gradient cen-
trifugation and incubated with IAb multimers (30 μg/ml) in Dulbecco’s modified Eagle’s medium supplemented with IL-2 (5 μmol/L) at 37°C for 3 hours. The cells 
were acquired using a FACSort, and the number of tetramer-PE (MOG35-55)-positive cells was then determined in live (7-AAD-negative) CD4-positive populations. 
Splenocytes from B6 mice immunized for 10 (effector) or 100 (memory) days with ovalbumin (Ova) were stained with MOG35-55 tetramer and used as control, con-
firming the specificity of the tetramer (representative of three independent experiments). C: Splenocytes from mice that received effector or memory T cells were cul-
tured with MOG35-55 peptide at 1, 10, and 100 μg/ml and cell proliferation was measured by [3H]thymidine incorporation. The proliferation rate was significantly 
higher in cultures from the memory () T cell group compared to the effector () group. D: Intracellular FACS staining of splenocytes from MOG35-55-immunized 
B6 mice. Spleen cells were isolated and activated in vitro with anti-TCR and anti-CD28 antibody for 6 hours and stained with anti-CD4-peridinin-chlorophyll-protein 
complex, anti-CD44-FITC, and a variety of cytokine-PE antibodies. **P < 0.001; ***P < 0.0001.
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Increased CNS Infiltration of Memory CD4+ T Cell-Mediated 
Inflammation during Eae
Histological examination of the CNS of TCRαβ-/- mice sacri-
ficed on day 12 and day 32 (Figure 3 and Table 2) postimmu-
nization revealed significantly more T cell infiltrates in CD4. 
memory T cell recipients (Figure 3A and Table 2) compared 
to CD4+ effector T cell recipients (Figure 3D and Table 2), and 
more microglia activation (Figure 3B versus 3E and Table 2). 
It should be noted that, unlike effector cell infiltration in the 
CNS, memory CD4+ T cell infiltrates and microglia activa-
tion were detected in the CNS through the late stages of the 
disease (day 32) (Figure 3 and Table 2). To analyze wheth-
er disease transfer affects axonal integrity, we used SMI32 
monoclonal antibody, which reacts with a nonphosphory-
lated epitope in neurofilament H in demyelinating axons, as 
a marker of axonal damage.29 We also used GFAP antibody, 
a marker of astrocytes that is induced during astrocytic ac-
tivation.30 Our data showed that memory CD4+ T cells were 
associated with greater astrocytic activation (Figure 3H) and 
axonal damage (Figure 3N), as demonstrated by increased 
fluorescence staining of GFAP and SMI32, respectively, com-
pared to recipients of effector cells (Figure 3, K and Q). A 
potential explanation for the increase in CNS infiltration in 
recipients of memory CD4+ T cells may be that memory T 
cells migrate to the CNS more efficiently. This is in agree-
ment with our present data of the mRNA and protein lev-
els of the chemokine receptor expression on MOG-specific 
memory CD4+ T cells demonstrating that these cells express 
higher levels of CXCR3 and CCR5 compared to effector CD4+ 
T cells, indicating that the severe disease induced by memo-
ry T cells is related, at least partially, to increased migration 
of these cells to the CNS.29
Costimulatory Requirements of Memory Versus Effector 
CD4+ T Cells in Vivo
Our group and others have shown previously that CD28-B7 
blockade by CTLA4Ig protects animals from actively induced 
EAE.31,32 As shown above, CD28 expression is higher in MOG 
TCR-specific effector T cells as compared to the memory T 
cell population (Figure 2; see Supplementary Figure S2, at 
http://ajp.amjpathol.org). To investigate the costimulatory 
requirements of memory and effector CD4+ T cells in vivo, 
TCRαβ-/- recipient mice that received either memory or ef-
fector CD4+ cells were treated with CTLA4Ig (200 μg) every 
2 days from day 0 through day 10 after immunization. The 
control group received control Ig. Our data demonstrated 
that although CTLA4Ig administration dramatically sup-
pressed the disease induced by transferring effector cells 
(mean maximal score 0.4 ± 0.1 versus 2 ± 0.2, P < 0.001; in-
cidence 25% versus 100%, P < 0.001), there was only a slight 
decrease in the induction of clinical disease in the group of 
CXCR3 protein levels were significantly higher in the memo-
ry T cells, whereas CTLA4 and CD28 protein expression was 
lower in the memory T cells compared to effector cells (Fig-
ure 2B), consistent with the mRNA data. The expression of 
OX40 was comparable between memory and effector T cells 
(Figure 2B).
We calculated the frequency of IFN-γ- and IL-17-producing 
cells at different time points. In the periphery (spleen and 
lymph node tissues), the frequency of IFN-γ-producing cells 
was higher in memory cells compared to effector cells on day 
8 (14.3% ± 1.4 versus 3.4% ± 0.5; P < 0.01), but the percentage 
of IL-17-producing memory cells was lower than that of ef-
fector cells (6.6% ± 0.3 versus 12.9% ± 1.3; P < 0.05) (Figure 
2C). Similarly, on day 14 (disease onset), the frequency of 
IFN-γ-producing cells remained higher in memory cells than 
effector cells (25.4% ± 2.3 versus 7.5% ± 1.2; P < 0.01) and the 
IL-17-producing cells lower than in the effector cell popula-
tion (3.2% ± 1.9 versus 16.1% ± 2.3; P < 0.01) (Figure 2C). In 
the CNS compartment (meningeal and spinal cord tissues), 
there were few cells on day 8, but by day 14 the frequency of 
IFN-γ-producing cells was higher in the memory population 
(32.4% ± 2.1 versus 15.7% ± 1.7; P < 0.05) and there was no 
difference in the frequency of IL-17-producing cells (Figure 
2C). Further analysis indicated similar frequencies of IL-4-, 
IL-5-, and IL-10-expressing cells between the two popula-
tions during all stages of the disease (data not shown). More 
importantly, at the very late stage of the disease (day 60), 
there was an exclusive infiltration of memory cells in the 
CNS (over 90% of transferred cells) of which 30.4% ± 6 were 
producing IFN-γ and 11.9% ± 3.5 were producing IL-17.
We calculated the relative frequency of transferred memory 
and effector T cells in the CNS compartment before, during, 
and after disease onset. During the presymptomatic disease 
phase (day 8), 59.3% ± 6.1 of the transferred cells were effec-
tor cells in the meninges, and no infiltrates were present in 
the target organ. However, at the peak of disease (day 14), 
the memory cells constituted 77.6% ± 6.6 of the transferred 
T cells in the CNS compartment (P < 0.005 compared to ef-
fector cells). The memory T cells predominated also during 
the late stage of the disease (day 60) (89.6% ± 7.6) in the CNS 
compartment (P < 0.001).
In another set of experiments, we explored the phenotype 
and migration of memory 2D2 Thy1.1 cells compared to 
naïve 2D2 Thy1.2 cells activated in vivo. Therefore, MOG-
specific memory (Thy1.1) and naïve (Thy1.2) were trans-
ferred into hybrid hosts and challenged with MOG35-55 
peptide. The FACS analysis indicated that the distribution 
of IFN-γ-producing cells was similar to our previous experi-
ments, with a higher frequency of IFN-γ-producing cells in 
the memory cell population in the periphery and in the CNS 
(Figure 2D). Unlike what we observed in the effector versus 
memory transfer, there was a slight increase in the frequency 
of memory IL-17-producing cells in the CNS (Figure 2D).
Table 1. Induction of Disease by Transfer of WT Memory, Effector, or Naïve CD4+ T Cells in TCRαβ-/- Mice
Group   Incidence   Mean day of onset ± SEM   Mean maximum score ± SEM   Death
Memory CD4+  16/16   12.0 ± 0.4     3.0 ± 0.2*     2/16
Naive CD4+  4/8   16.0 ± 0.9     0.8 ± 0.4**     0/8
Effector CD4+  16/16   13.5 ± 0.6     2.2 ± 0.2     0/16
TCRαβ-/- mice received naïve, effector, or memory CD4+ T cells on day 0 and were immunized on the same day with MOG35-55 peptide emulsified in CFA and 
monitored for the development of EAE. Statistical analysis was performed using the Mann-Whitney test.
*P = 0.006; **P < 0.0001
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production by the effector T cell recipients treated with anti-
B7h was similar to that of recipients treated with control Ig 
(Figure 4D).
We tested the effect of OX40L-OX40 blockade in this model 
using a blocking antibody against OX40L. TCRαβ-/- mice re-
ceived either memory or effector CD4+ T cells in the presence 
of anti-OX40L (200 μg) every second day from day 0 through 
day 10 after immunization. Surprisingly, antibody treatment 
ameliorated disease in recipients of memory (mean maximal 
grade 2.9 ± 0.1 vs. 1.7 ± 0.4, P < 0.01) and effector CD4+ T 
cells (mean maximal grade 2 ± 0.2 versus 1.2 ± 0.2, P < 0.05) 
(Figure 4E). The frequency of IFN-γ-producing cells was 
decreased in the anti-OX40L-treated memory cell recipients 
(P < 0.05) as well as the effector cell recipients treated simi-
larly (P < 0.01) (Figure 4F). The amelioration of the clinical 
score induced by OX40-OX-40L pathway blockade was as-
sociated with enhanced IL-10 production and reduction of 
IFN-γ-producing lymphoid cells of memory and effector T 
cell recipients, whereas IL-17 production was not affected 
(Figure 4F).
Discussion
The success of experimental immunomodulatory and tol-
erance strategies has been largely restricted to naïve hosts 
that do not harbor significant numbers of memory T cells; 
for example, mice housed in a pathogen-free environment. 
These strategies induce immunological tolerance to a foreign 
antigen by exploiting the same principles that underlie toler-
ance to self-antigens: deletion, anergy, regulation, and im-
mune deviation. Therefore, for such strategies to work in im-
munologically experienced hosts, such as humans, relevant 
experimental models must first be developed to address 
whether memory T cells can be “tolerized” in vivo. The role 
mice that received memory cells (mean maximal grade 2 ± 
0.2 compared to 2.5 ± 0.1, P = 0.03) (Figure 4A), and overall 
disease incidence was similar to the control group (100%). 
We investigated the cytokine profile in treated mice. Spleen 
and lymph node cells were isolated from treated mice 12 
days after immunization and exposed to MOG peptide (50 
μg/ml), and the cytokine profile was characterized. The ef-
fects of in vivo CTLA4Ig administration on the frequency of 
IFN-γ-producing cells were evident in mice that received ef-
fector cells (P < 0.01) and to a lesser extent in the mice that 
received memory cells (P < 0.05) (Figure 4B). Interestingly, 
CTLA4Ig administration increased IL-10 production and in-
hibited IL-17 production in cells isolated from the effector T 
cell recipients (P < 0.05 compared to control Ig-treated mice), 
whereas no such effects were seen in the memory T cell re-
cipients (Figure 4B).
Next, TCRαβ-/- mice that received either memory or effector 
CD4+ cells were treated i.p. with anti-B7h (ICOS-L) (200 μg) 
every second day from day 0 through day 10 after immuni-
zation. Although anti-B7h antibody treatment worsened the 
disease induced by transferring effector cells (mean maximal 
grade 2 ± 0.2 versus 2.6 ± 0.1, P < 0.05), it provided signifi-
cant protection in mice that received memory cells (mean 
maximal grade 2.9 ± 0.1 versus 1.8 ± 0.1, P < 0.005) (Figure 
4C). In vitro, the cytokine profile of lymphoid cells isolated 
12 days after immunization resembled in vivo disease, with 
decreased frequency of IFN-γ-producing cells (P < 0.05) in 
the memory cell recipients treated with anti-B7h compared 
to control Ig mice. There was no such decrease in effector 
cell recipients treated similarly (Figure 4D). Furthermore, 
lymphoid cells from memory T cell recipients produced 
significantly less IL-17 and more IL-10 after treatment with 
anti-B7h (P < 0.05 compared to control mice), whereas IL-17 
Figure 2. Competitive assay of MOG-specific mem-
ory, effector, and naïve activated CD4+ T cells. A: A 
total of 1 × 106 MOG-TCR transgenic effector CD4+ 
(CD4+CD44hi, from day 10 postimmunization, Δ‚) or 
1 × 106 memory CD4+ (CD4+CD44hi, from day 100 
postimmunization, ■) were transferred into TCRαβ-/- 
mice (n = 6 to 8) that were immunized with MOG35-
55. Disease induced by MOG-TCR transgenic mem-
ory CD4+ cells was more severe than that induced by 
effector CD4+ cells (mean maximal score 3.8 ± 0.4 ver-
sus 2.8 ± 0.1, P = 0.004), although the time to onset was 
similar in the two groups. B: Phenotypic character-
ization of MOG TCR-specific memory, effector, and 
naïve CD4+ T cells. Cells were stained for different 
markers and analyzed by flow cytometry. Results are 
expressed as MFI. C: Time course- and tissue-specific 
analysis of cytokine profile of autoreactive memory 
(Thy1.1) and effector (Thy1.2) CD4+ T cells that were 
transferred into Thy1.1/Thy1.2 hybrid recipients. D: 
Another set of experiments was performed to com-
pare memory (Thy1.1) to naïve-activated (Thy1.2) T 
cells in other hybrid recipients. Cells were collected 
from the peripheral organs (spleens and lymph 
nodes) and from the CNS compartment (meninges 
and spinal cords) and analyzed by flow cytometry 
before EAE onset (Presymptomatic) and at the peak 
of the disease (Onset) in the periphery and the CNS. 
Data represent the percentage of cytokine-positive 
cells and the mean fluorescence intensity of the sur-
face molecule expression. Bars represent SEM values. 
*P < 0.05; **P < 0.001.
418 Elyaman, KivisäKK, REddy, Chitnis, Raddassi, imitola, BRadshaw, KuChRoo, yagita, sayEgh & KhouRy in AmericAn JournAl of PAthology (august 2008) 173(2)
abundance of memory T cells in the target organ occurred 
under non-lymphopenic conditions, suggesting that this per-
sistence was not due to homeostatic proliferation-mediated 
accumulation of memory T cells. Moreover, in comparison to 
effector T cells, we demonstrated that memory T cells were 
less susceptible to activation-induced cell death and exhib-
ited higher expression of the anti-apoptotic Bcl-2, whereas 
effector cells expressed higher levels of the death receptor 
tumor necrosis factor receptor p55 and caspase-8, which are 
known to interact physically to induce the pro-apoptotic pro-
tease cascade.35 Although the frequency of long-term mem-
ory MOG-specific T cells was lower than that of short-term 
effector cells, the higher proliferative capacity of memory 
cells could be linked to a lower susceptibility to AICD. In-
terestingly, we also showed that memory CD4+ T cells have 
increased expression in the Th1-associated chemokine recep-
tor, CXCR3, and increased IFN-γ production compared to 
effector CD4+ T cells. A recent report showed that CXCR3 
is required for recruitment of CD62L and CCR7-negative 
memory T cells to reactive lymph nodes of adjuvant inocula-
tion.36 Thus, the memory T cells that we isolated from pe-
ripheral lymphoid organs of immunized mice are heteroge-
neous in the expression of these homing receptors since they 
are a mixture of TCM and TEM. Memory CD4+ T cells infiltrated 
more than effector T cells and persisted until the late stage of 
the disease. These data are consistent with previous reports 
showing that CXCR3 is expressed on memory CD4+ T cells 
and preferentially on activated Th1 cells37 and that a small-
molecule compound targeting CXCR3 prevents acute and 
chronic allograft rejection in murine cardiac and islet trans-
plant models.38 Other reports demonstrated that the role of 
CXCR3 is not limited to T cell migration and could play an 
important role in the differentiation of memory CD4+ T cells 
during inflammation in humans.39,40 In contrast to the impli-
cation of CXCR3 in migration, it recently was demonstrated 
that CXCR3-/- mice exhibit exaggerated severity of EAE com-
pared with wild-type (CXCR3+/+) littermate mice.39 There 
were neither quantitative nor qualitative differences in CNS-
infiltrating leukocytes between CXCR3+/+ and CXCR3-/- mice 
with EAE.41 Although the discrepancies between the findings 
of the two groups highlight the need for further study, the 
expression of this chemokine receptor at high levels in mem-
ory CD4+ T cells suggests an important role in memory T cell 
migration and perhaps in memory T cell differentiation.
For the first time we compare the in vivo behavior of mem-
ory and effector T cells in the same recipient. We also show 
that in addition to the production of IFN-γ, memory CD4+ 
of heterologous memory cells has been recognized as a bar-
rier to transplantation tolerance.33 It is becoming clear that 
results from current experimental models of autoimmune 
disease may not predict outcomes in human studies; thus, 
it is critical to develop animal models that address the role 
of memory T cells in response to therapeutic strategies.<b.
To address this issue, we developed a new disease model of 
memory CD4+ T cell-induced EAE. We validated this model 
using both wild-type and MOG TCR-specific cells to avoid 
any bias related to the high precursor frequency of trans-
genic cells.34 We showed that memory CD4+ T cells induced 
more severe EAE than did their effector or naïve counter-
parts. The disease induced by memory cells was associated 
with increased cell proliferation, Th1 cytokine production, 
and more severe CNS infiltration and axonal damage. The 
Table 2. Quantification of CNS-Infiltrating T Cells in Recipients of Memory or 
Effector T Cells by Immunohistology
      Memory    Effector
      group     group     Comparison
Day 12
 CD4+ T cells   68.8 ± 13.8    43.5 ± 7.7    P < 0.05
 Lectin B4+ cells  34.5 ± 7.9    27.8 ± 14.9    P = 0.45
Day 32
 CD4+ T cells   107 ± 21    22 ± 4     P < 0.005
 Lectin B4+ cells  76 ± 12     21 ± 6     P < 0.005
TCRαβ-/- mice received effector or memory CD4+ T cells on day 0 and were 
immunized on the same day with MOG35-55. Spinal cords from each group 
of animals were collected on day 12 and day 32 postimmunization, processed 
for frozen sectioning, and immunostained for CD4 and lectin B4. Statistical 
analysis was performed using an unpaired t-test. P values < 0.05 were consid-
ered significant.
Figure 3. Inflammatory cell infiltrates in the CNS of TCRαβ-/- mice recipients 
of memory versus effector CD4+ T cells. Spinal cord tissues from the recipients 
of memory CD4+ T cells (A-C, G-I, and M-O) or effector CD4+ T cells (D-F, 
J-L, and P-R) were harvested 32 days postimmunization, processed for frozen 
sectioning, and immunostained with rat anti-CD4 (A, D, G, J, M, and P; red), 
anti-lectin B4 (B and E; green), anti-GFAP (H and K; green), and mouse anti-
SMI32 (N and Q; green). Sections were co-stained with the nuclear dye TOPO3 
(blue). Merged pictures (C, F, I, L, O, and R) are shown of images captured 
using confocal imaging at ×63 magnification.
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caused weak protection of EAE induced by memory cells and 
did not suppress the production of pro-inflammatory cytok-
ines IFN-γ and IL-17, in contrast to the effective suppression 
of effector cell-induced disease that we usually obtain with 
the same regimen of CTLA4Ig.
Recent studies identified a novel costimulatory pathway in-
volved in the activation of antigen-experienced but not naïve 
T cells.17 The pathway is activated by the interaction of ICOS 
on T cells with B7h (B7RP-1) on antigen-presenting cells.53 
Costimulation through ICOS is crucial for the activation of 
previously primed T cell populations, which include memory 
T cells. Blocking this pathway in EAE during the efferent im-
mune response (9 to 20 days after immunization) abrogated 
disease, whereas blockade during antigen priming (1 to 10 
days after immunization) exacerbated disease.54 Our model 
has the advantage of unequivocally showing the differen-
tial effect of ICOS blockade on effector versus memory cells. 
Our present findings also demonstrate that the decrease in 
expression of mRNA and protein level of ICOS has function-
al relevance. It is noteworthy that Park et al.45 have shown 
that the ICOS-B7h pathway is required for the production 
of IL-17 in murine T cells. These data are consistent with our 
present findings that blockade of B7h was beneficial when 
EAE was induced by transfer of CD4+ memory cells and was 
associated with a decrease in IL-17 production, whereas it 
worsened the disease when induced by transfer of CD4+ ef-
fector cells. It is also striking that ICOS mRNA is expressed 
at a significantly higher level on memory T cells compared 
to effector cells, which is consistent with an important role 
of the ICOS-B7h pathway in memory T cell-induced EAE. 
It is commonly stated that activation of memory T cells is 
independent of costimulatory signals; however, our in vivo 
T cells produced IL-17, although this production was lower 
than that of effector cells. IL-17 expression has been linked to 
autoimmune diseases, although its regulation and function 
are still unclear.42,43 Two recent studies showed evidence that 
IL-17-producing effector CD4. T cells develop via a lineage 
distinct from the Th1 and 2 lineages.44,45 This process is nega-
tively regulated by T helper type 1 and type 2 cytokines.45 
Interestingly, we observed reduced production of IL-17 as-
sociated with increased secretion of IFN-γ by memory T cells 
compared to their effector counterparts during EAE. This 
suggests that IFN-γ may down-regulate IL-17 in the memory 
population. One of the approaches to targeting autoimmune 
disease mediated by memory T cells is to block activation 
pathways unique to the recall of memory T cells. There is 
extensive evidence in vitro that human memory T cells do 
not require CD28 costimulation for full activation.19,20,46,47 On 
the other hand, there are no in vivo studies of the effect of 
CTLA4Ig on memory function in an autoimmune disease 
model. Recently, two reports about CD28-mediated costim-
ulation in viral models of CD4+ and CD8+ memory T cells 
demonstrated that the CD28 costimulatory pathway block-
ade suppressed memory T cell activation.21,22 Previously, we 
and others showed the effectiveness of the costimulatory 
signal blocker CTLA4Ig in EAE,31,48-50 but we hypothesized 
that CTLA4Ig would not be sufficient to induce tolerance of 
memory T cells.51,52 A clinical trial of CTLA4Ig in MS is cur-
rently under way (S.J. Khoury and colleagues), so it is critical 
to understand the limitations of such an approach in treating 
human disease. In this report, we showed that the numbers 
of CD28 and CTLA4 transcripts were lower in MOG-specific 
memory T cells compared to effector and naïve T cells. Fur-
thermore, blocking CD28-B7 costimulation with CTLA4Ig 
Figure 4. Differential role of costimulatory molecules in disease induced by CD4+ memory and effector T cells. A: Effects of CTLA4Ig on the clinical disease induced 
by the transfer of effector or memory cells into TCRαβ-/-. B: ELISPOT data of the frequency of IFN-γ-, IL-10-, and IL-17-producing cells. Spleen cells were exposed 
to MOG peptide (50 μg/ml) for 48 hours and positive cells were quantified. C: Effects of anti-ICOS-L on the clinical disease induced by effector or memory cells. D: 
ELISPOT analysis of the frequency of cells producing IFN-γ, IL-10, and IL-17 was performed using spleen cells isolated from mice recipients of memory or effector 
T cell. E: Blockade of OX40 costimulatory pathway using anti-OX40L monoclonal antibody in EAE induced by the memory or effector T cells. F: ELISPOT data of 
the cytokine profile of memory and effector CD4+ T cells exposed to anti-OX40L or control IgG during EAE. Representative of two separate experiments (n = 8 mice 
per group). *P < 0.05; **P < 0.01.
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studies demonstrate that memory T cells are sensitive to co-
stimulatory blockade but have different requirements from 
effector T cells.
The OX40-OX40L pathway appears to regulate multiple 
aspects of the T cell response. OX40 costimulation on effec-
tor T cells promotes cell survival, proliferation, and effector 
differentiation.55 Also, OX40 costimulation prevents T cell 
anergy and allows anergic T cells to acquire potent effector 
functions.56 Furthermore, OX40 is instrumental in the gen-
eration of the memory recall response. Studies using OX40-
deficient mice clearly showed that the most profound impact 
of OX40 deficiency on the immune response is the impaired 
generation of memory T cells.57,58 Recently, in a mouse model 
of skin transplantation, memory T cells generated by homeo-
static proliferation and resistant to CD28/CD154 blockade in 
transplant rejection are sensitive to OX40 blockade.59 This is 
in agreement with our present findings in which anti-OX40L 
therapy ameliorated EAE mediated by memory T cells and 
reduced IFN-γ-producing cells.
In our model, the percentage of CD4+CD25+Foxp3+ cells 
in the transferred population was comparable between the 
effector and memory populations. After immunization, the 
percentages of these CD4+CD25+Foxp3+ cells remained simi-
lar in the two groups. These data underscore that differential 
expansion of regulatory T cells is not the cause of disparity 
in disease severity between the effector and memory T cell 
recipients. Our findings also suggest that regulatory T cells 
may have less ability to control memory than effector T cells 
in vivo.
In conclusion, we provide a clinically relevant novel model 
of autoimmune disease mediated by memory T cells that is 
useful for the study of disease pathogenicity as well as for 
the investigation of immunological tolerance strategies.
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